Energy Deficiency-Induced ATG4B Nuclear Translocation Inhibits DNA Repair and Promotes Leukemia Progression

Study Background and Research Question

Metabolic alterations and genomic instability are widely recognized as central features in cancer biology, yet the mechanistic interplay between these two processes is incompletely understood. While energy metabolism has been implicated in modulating DNA repair by influencing nucleotide synthesis, chromatin remodeling, and reactive oxygen species (ROS) levels, the direct molecular connections between cellular energy status and DNA repair fidelity remain elusive (reference). This knowledge gap is of particular significance in acute myeloid leukemia (AML), where high mutation burdens and metabolic dysregulation contribute to disease progression and therapeutic resistance. The referenced study sought to elucidate whether and how cellular energy deficiency directly impairs DNA repair mechanisms in AML cells, with a focus on the autophagy-related protein ATG4B and its interaction with the DNA repair machinery.

Key Innovation from the Reference Study

The central innovation of this research is the identification of a novel axis by which energy deficiency drives nuclear translocation of ATG4B, leading to inhibition of PRMT1-mediated DNA repair. Specifically, the study reveals that under energy stress, ATG4B relocates from the cytoplasm to the nucleus, where it binds to protein arginine methyltransferase 1 (PRMT1). This interaction blocks PRMT1-dependent methylation of MRE11, a protein critical for the repair of DNA double-strand breaks, thereby reducing DNA repair capacity and promoting genomic instability (reference).

Methods and Experimental Design Insights

The investigators employed a multifaceted approach combining cellular, molecular, and in vivo models to dissect the energy metabolism–DNA repair interface:

• Energy Deficiency Induction: AML cell lines and patient-derived AML cells were subjected to glucose deprivation and pharmacological inhibitors to induce cellular energy deficiency.
• Subcellular Fractionation and Imaging: Subcellular localization of ATG4B was tracked by immunofluorescence and nuclear-cytoplasmic fractionation, confirming its nuclear translocation under energy stress.
• Protein Interaction Mapping: Co-immunoprecipitation and mass spectrometry were used to demonstrate direct binding between ATG4B and PRMT1 in the nucleus.
• DNA Repair Assays: DNA double-strand break repair was assessed via γH2AX foci resolution and comet assays.
• Genomic Instability and Mutation Burden: Whole-exome sequencing and mutation frequency analyses were performed in AML models.
• In Vivo Models: Both murine AML models (MLLT3-KMT2A overexpression) and AML patient-derived xenografts were used to evaluate disease progression and survival upon genetic or pharmacologic inhibition of ATG4B.

Protocol Parameters

• assay | whole-exome sequencing | 100x coverage | AML models | to quantify mutation burden under various metabolic conditions | paper
• assay | γH2AX foci assay | 24-48 h post-treatment | AML and control cell lines | measures DNA double-strand break repair kinetics | paper
• assay | glucose deprivation | 0.5-2 mM glucose | in vitro AML models | induces energy deficiency for mechanistic studies | paper
• assay | immunofluorescence microscopy | 40x magnification | nuclear localization studies | visualize ATG4B translocation | paper
• assay | ATG4B inhibitor (screened in vitro) | 1-10 μM | functional rescue experiments | test whether ATG4B inhibition restores DNA repair | paper
• assay | antifungal drug (e.g., Tioconazole) | 1-50 μM | fungal infection model | explore ergosterol biosynthesis inhibition in parallel metabolic-genomic studies | workflow_recommendation

Core Findings and Why They Matter

The study’s most consequential findings are as follows:

• ATG4B Nuclear Translocation: Under energy-deficient conditions, ATG4B accumulates in the nucleus, an event not observed in energy-replete states (reference).
• Disruption of DNA Repair Machinery: Nuclear ATG4B directly interacts with PRMT1, inhibiting PRMT1-dependent methylation of MRE11. This post-translational modification is essential for efficient DNA double-strand break repair.
• Genomic Instability: Impaired MRE11 methylation leads to defective DNA repair, increased mutation burden, and genomic instability in AML cells.
• AML Progression and Therapeutic Implications: ATG4B-mediated DNA repair defects were markedly enhanced in both patient-derived and murine AML models. Notably, pharmacologic or genetic inhibition of ATG4B restored PRMT1-mediated DNA repair, reduced mutation burden, and prolonged survival in AML-bearing mice (reference).

These results provide a mechanistic explanation for how cancer cell metabolic stress can exacerbate genomic instability and disease progression, while positioning ATG4B as a potential therapeutic target in leukemia.

Comparison with Existing Internal Articles

Several internal resources discuss the intersection of metabolism, genomic stability, and antifungal drug development, offering complementary perspectives to the present study:

• Tioconazole and the Future of Antifungal Research explores how Tioconazole-mediated inhibition of ergosterol biosynthesis intersects with fungal cell metabolic pathways, drawing parallels to oncology research by highlighting the importance of metabolic-genomic crosstalk in both domains (internal).
• Tioconazole: Mechanistic Leverage and Strategic Vision for Antifungal Translational Research further contextualizes the broader implications of metabolic regulation in antifungal and cancer biology, emphasizing translational opportunities for researchers investigating cell metabolism and genomic maintenance (internal).
• These internal articles provide practical frameworks for leveraging antifungal agents such as Tioconazole in research models of metabolic-genomic interaction, though their primary focus is on fungal infection models rather than leukemia.

Limitations and Transferability

While the study convincingly establishes a direct link between energy deficiency, ATG4B nuclear translocation, and impaired DNA repair in AML, several limitations must be acknowledged. First, the work is centered on leukemia models and may not be directly generalizable to solid tumors or other hematological malignancies. Second, the specific molecular determinants governing ATG4B nuclear import under energy stress require further elucidation. Finally, clinical translation remains in its infancy; the efficacy and safety of ATG4B-targeted therapies in humans are yet to be established (reference).

Why this cross-domain matters, maturity, and limitations

This research bridges the fields of metabolic regulation and genomic stability in oncology, echoing themes found in antifungal drug development where metabolic disruption (e.g., ergosterol biosynthesis inhibition by azole antifungals) leads to compromised cell membrane integrity and cell survival. Such cross-domain insights foster the design of experimental models that interrogate how metabolic stress influences DNA repair, mutation rates, and resistance evolution—both in cancer and in fungal infection systems. However, direct mechanistic transfer between fungal and mammalian cells should be approached with caution, as the regulatory networks and molecular players differ substantially (internal).

Research Support Resources

Researchers interested in modeling metabolic-genomic crosstalk, whether in oncology or antifungal studies, may benefit from validated inhibitors that target specific metabolic pathways. For antifungal research, Tioconazole (SKU B2051) is available as a high-purity antifungal medication with well-characterized solubility and mechanism as a fungal cytochrome P450 inhibitor disrupting ergosterol biosynthesis. This compound is suitable for use in in vitro antifungal assays and fungal infection models, supporting studies that parallel those described in the AML–metabolism–genomic instability axis (source: product_spec). For protocols, storage, and handling recommendations, consult the supplier's documentation. This resource can facilitate the design of metabolic intervention experiments in the context of antifungal drug development and resistance modeling.